We demonstrated that EGFR hyperactivation, due to aberrant regulation of AP1 complex members, drives a proliferative phenotype in RET fusion-positive NSCLC cells resistant to BLU-667 and LOXO-292. This evidence concerns the gene EGFR and non-small cell lung carcinoma.